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Neurotrophic factors (NTFs) are involved in the regulation of neuronal survival and function and, thus, may be 
used to treat neurological diseases associated with neuronal death. A major hurdle for their clinical application is 
the delivery mode. We describe here a new strategy based on the use of progenitor cells called mesoangioblasts 
(MABs). MABs can be isolated from postnatal mesoderm tissues and, because of a high adhesin-dependent 
migratory capacity, can reach perivascular targets especially in damaged areas. We generated genetically modi-
fied MABs producing nerve growth factor (MABs-NGF) or brain-derived neurotrophic factor (MABs-BDNF) 
and assessed their bystander effects in vitro using PC12 cells, primary cultures, and organotypic cultures of 
adult hippocampal slices. MABs-NGF-conditioned medium induced differentiation of PC12 cells, while MABs-
BDNF-conditioned medium increased viability of cultured neurons and slices. Slices cultured with MABs-
BDNF medium also better retained their morphology and functional connections, and all these effects were 
abolished by the TrkB kinase blocker K252a or the BDNF scavenger TrkB-IgG. Interestingly, the amount of 
BDNF released by MABs-BDNF produced greater effects than an identical amount of recombinant BDNF, sug-
gesting that other NTFs produced by MABs synergize with BDNF. Thus, MABs can be an effective vehicle for 
NTF delivery, promoting differentiation, survival, and functionality of neurons. In summary, MABs hold distinct 
advantages over other currently evaluated approaches for NTF delivery in the CNS, including synergy of MAB-
produced NTF with the neurotrophins. Since MABs may be capable of homing into damaged brain areas, they 
represent a conceptually novel, promising therapeutic approach to treat neurodegenerative diseases. 
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neurotrophic factor (BDNF). A vast literature shows that 
NGF and BDNF exert trophic and neuroprotective effects 
on neurons, but their clinical use is hindered by a short 
biological half-life, a poor blood–brain barrier (BBB) 
permeability, and side effects due to their pleiotropic 
systemic actions (2). Given these difficulties, the atten-
tion turned into the development of techniques that allow 
local delivery based on gene therapy (49,61) or on cell-
mediated approaches. 
Stem cell-mediated gene delivery, by which stem cells 
are genetically modified with NTFs and then transplanted 
INTRODUCTION
Neurotrophic factors (NTFs) are critical for the survival, 
development, and function of neurons in the mammalian 
central nervous system (23). Alterations in NTFs or their 
receptors leading to loss of function can cause neuronal 
death and contribute to the pathogenesis of neurodegenera-
tive diseases and of diseases associated with neuronal dam-
age (4,7,11,67). Not surprisingly, therefore, they received 
considerable interest as therapeutic agents (5,56,60). 
A particular attention has been devoted to the neuro-
trophins nerve growth factor (NGF) and brain-derived 
1614 SU ET AL.
into the brain, is emerging as a promising strategy. This 
strategy has been already validated for several lines 
of stem cells, including neural (26,39,42), embryonic 
(34,40,52), and mesenchymal stem cells (20,36,54): when 
engineered to produce NTFs, these cells were found to 
ameliorate experimental neurodegenerative diseases or 
injuries. The advantages of using genetically modified 
stem cells as grafts include the fact that they could exert 
not only long-term functional integration but also repair 
capabilities and that they can ensure a continuous and 
concentrated local supplementation of diffusible thera-
peutic molecules (like NGF or BDNF), reducing nonse-
lective delivery, and allowing high treatment ef ficiencies 
for long time periods. However, the downside of these 
approaches is that they require an invasive delivery route 
to the target location in the nervous system, a problem 
that severely limits their potential for human therapy.
These considerations prompt the search for alterna-
tive cell sources that display more favorable homing 
properties, avoiding the necessity of a direct injection 
into the brain. Here, we explored the feasibility of a new 
approach: the use of multipotent, mesodermal progenitor 
cells [mesoangioblasts (MABs)] that constitutively pro-
duce a subset of NTFs [e.g., vascular endothelial growth 
factor B (VEGF B), fibroblast growth factor-2 (FGF-2), 
FGF-7, platelet-derived growth factor AA (PDGF)] and 
can be engineered to produce others. MABs are an afford-
able cellular source since they can be isolated from small 
biopsies of postnatal human skeletal muscle and have 
already been utilized for regenerative purposes in large 
animal models, besides rodents (47,53). More impor-
tantly, a phase I/phase II cell therapy trial with donor 
MABs for patients affected by Duchenne muscular dys-
trophy is planned for year 2011 (59). 
MABs have a high, adhesin-dependent, migratory 
capacity and the ability to cross the vessel wall and reach 
perivascular targets, a property not demonstrated so far 
for mesenchymal stem cells. Their chemotactic ability 
is increased under inflammatory conditions, when the 
adhesin–integrin system and diapedesis moving are acti-
vated (16). When peripherally administered, therefore, 
MABs may selectively cross the BBB and home into 
lesioned brain parenchyma. These cells express several 
neuro-ectodermal genes, but they do not differentiate into 
neurons (58). Thus, they may not be used for a restorative 
engraftment. Instead, MABs are expected to act as a res-
ervoir and delivery system for NTFs.
The aim of this study was to engineer MABs to pro-
duce and secrete NGF or BDNF and to examine their 
bystander effects. Thus, the medium collected from MAB 
cultures (containing either NGF or BDNF plus other con-
stitutively produced NTFs) has been applied to PC12 
cells, primary neuronal cultures (PC), and organotypic 
cultures (OC) of adult hippocampal slices. 
MATERIALS AND METHODS
Expression Vectors
Murine preproNGF and rat preproBDNF cDNAs have 
been PCR amplified from pTrcHisA-preproNGF and pBK-
CMV-preproBDNF using the following XhoI-5¢and NotI-3¢ 
primers: 5¢ primer-GTCGACCTCGAGGTAATGTCCAT 
GTTGTTCTACACTCTG and 3¢ primer-AGTCGGCTG-C 
GGCCGCTCAGCCTCTTCTTGTAGCCTTCCT for NGF; 
5¢ primer-GTCGACCTCGAGAT-GACCATCCTTTTC 
CTTACTATG and 3¢ primer-AGTCGGCTGCGGCCGC 
CTATCTTCCCC-TTTTAATGGTCAG for BDNF. The 
PCR reaction has been performed with proofreading Pfu 
DNA polymerase (Promega, WI, USA) using the follow-
ing conditions: 95°C, 1 min; 55°C, 1 min; 72°C, 1 min, 
for 25 cycles. Amplified preproNGF and preproBDNF 
cDNAs have been sequenced with the CEQ DTCS Quick 
Start Kit (Beckman Coulter, Inc., CA, USA) and then Xho/
NotI cloned into the single chain variable fragment (ScFv) 
express eukaryotic vector (50) to produce ScFv-preproNGF 
and ScFv-preproBDNF constructs, respectively.
Transfection of Cells and Neurotrophin Quantification
COS cells (5 × 105; from the American Type Culture 
Collection, ATCC), grown for 1 day in Dulbecco’s modi-
fied Eagle’s medium (DMEM) plus 10% fetal bovine 
serum (FBS), were transiently transfected with ScFv-
preproNGF or ScFv-preproBDNF using Fugene, accord-
ing to the manufacturer’s instructions (Roche, Basel, CH). 
NGF and BDNF expression and secretion were evaluated 
on the conditioned medium 72 h after transfection.
Green fluorescent protein (GFP)-expressing MABs 
(45), grown in DMEM plus 10% FBS, have been stably 
transfected with the expression vectors ScFv-preproNGF 
or ScFv-preproBDNF using Lipofectamine (Invitrogen, 
CA, USA), according to manufacturer’s instructions. Upon 
G418 selection, single clones of stable transfectants have 
been cultured with the ordinary methods, using the fol-
lowing culture medium (here referred to as Medium-1): 
88% DMEM, 10% FBS, 0.5% GlutaMaxII, 22 mM mg/
ml glucose, 1 mM sodium pyruvate, 100 U/ml penicillin, 
and 100 mg/ml streptomycin (all from Gibco, Invitrogen, 
CA, USA). The production of exogenous neurotrophins was 
analyzed by a “two-site sandwich” ELISA (8), performed 
on the medium collected from NGF- and BDNF-producing 
MABs. The medium was collected and centrifuged for 
5 min at 230 × g, and then the supernatant was collected. The 
supernatant consists of the medium containing the soluble 
substances secreted by MABs, including NGF in the case of 
MABs-NGF and BDNF in the case of MABs-BDNF. NGF 
and BDNF “coating” were performed using anti-NGF mAb 
aD11 (1 ng/ml) and IgG-TrkB immunoadhesin (5 ng/ml), 
respectively. The following antibodies were used for 
ELISA: rabbit polyclonal anti-mNGF (30 mg/ml, Sigma, St. 
Louis, MO, USA); chick polyclonal anti-hBDNF (1 mg/ml, 
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Promega, WI, USA); biotinylated anti-rabbit secondary anti-
body (1:1,000, Vector Laboratories, Inc., CA, USA); bioti-
nylated anti-chick secondary antibody (1:1,000, Promega, 
WI, USA). As standards, recombinant 2.5S mNGF and 
hBDNF (Alomone Labs Ltd., Jerusalem, Israel) were used. 
Immunoreactivity was visualized with the ABC kit (Vector 
Laboratories) using tetramethylbenzidine (TMB) as sub-
strate. Data are reported as average of at least two indepen-
dent experiments, each performed in duplicate.
Western Blot Analysis. MABs-NGF (clone F10) and 
MABs-BDNF (clone A9) were compared with control 
MABs. The conditioned media were collected from cells 
grown for 3 days. Samples of conditioned media were sepa-
rated by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE; 10% acrylamide), and proteins were 
transferred onto Hybond-C nitrocellulose in transfer buffer 
(25 mM Tris, 192 mM glycine, 20% v/v methanol) for 1 h at 
50 mA. The membrane was blocked for 12 h at 4°C in 5% 
milk–PBS (w/v). The following antibodies were used: rabbit 
polyclonal anti-murine NGF (30 μg/ml, 1:1,000; Sigma); rab-
bit polyclonal anti-BDNF (1:600; Santa Cruz Biotechnology); 
horse radish peroxidase (HRP) anti-rabbit (1:7,000 for NGF, 
1:3,000 for BDNF) as secondary antibody. For NGF, the pri-
mary antibody was diluted in PBS–5% milk and incubated 
1 h at room temperature; for BDNF, it was diluted in PBS–
2.5% milk–1% bovine serum albumin (BSA) and incubated 
overnight at 4°C. Washes were performed in PBS–0.05% 
Tween and then PBS 1×. Membranes were developed using 
the ABC (Vector Laboratories) followed by the Amersham 
ECL kit (GE Healthcare, Little Chalfont, UK).
Assessment of NGF Biological Activity
PC12 Cells. PC12 cells (ATCC) (19) have been cul-
tured in RPMI (Invitrogen, CA, USA) plus 10% FBS. 
Upon washing in serum-free medium, 4 × 105 PC12 cells 
were plated in 35 mm collagen-treated Petri dishes in the 
following different conditions: alone, in coculture with 
the same amount of MABs-NGF, in the presence of a 
5-day-culture supernatant from MABs and MABs-NGF, 
or in the presence of recombinant NGF (50 ng/ml). PC12 
cells were maintained in culture for 7 days, replacing 
fresh medium every 2 days. Neuronal differentiation was 
evaluated by the presence of neurite processes in the cul-
tures and confirmed by b-tubulin immunofluorescence. 
For b-tubulin and GFP expression in PC12/MABs 
coculture, cells were fixed in 4% paraformaldehyde (PFA), 
washed briefly in phosphate-buffered solution (PBS), and 
permeabilized with 0.1% Triton in PBS. After blocking in 
10% normal goat serum (NGS), cells were stained with 
mouse anti-b III tubulin antibody TuJ1 (1:250, Covance, 
NJ, USA) and rabbit anti-GFP antibody (1:500; Invitrogen, 
CA, USA), followed by Alexa Fluor 594-conjugated anti-
mouse and Alexa Fluor 488-conjugated anti-rabbit anti-
bodies (1:500; Invitrogen, CA, USA).
Assessment of BDNF Biological Activity 
Primary Hippocampal Neuronal Cultures. Primary 
hippocampal neuronal cultures (PCs) were derived 
from P0 newborn Swiss mice (Harlan Italy, San Pietro al 
Natisone, Italy). The use of animals for these experiments 
and for those described below was authorized by the ethi-
cal committee for animal experiments of the University 
of Ferrara and by the Italian Ministry of Health (autho-
rization number 36/2008). Hippocampi were dissected 
and minced with forceps, and then completely dissoci-
ated into a single-cell suspension using trypsin digestion. 
Isolated hippocampal cells were plated at a low density of 
approximately 5 × 104 cm−2 viable cells in 24-well plates 
coated with poly-l-lysine (Sigma, St. Louis, MO, USA). 
Cells were grown in DMEM supplemented with 10% 
FBS, 50 U/ml penicillin, and 50 mg/ml streptomycin. 
The culture medium was replaced with the different con-
ditioned media (see below) supplemented with 5 μM ara-
binofuranosyl cytidine (Ara-C) at the day after plating. 
Organotypic Hippocampal Slice Cultures. Hippocam-
pal organotypic slice cultures (OCs) were prepared as 
described by Stoppini et al. (57) with slight modifications. 
Male Swiss mice (4 weeks old, Morini Co., Italy) were 
briefly anesthetized by diethyl ether and decapitated. The 
brains were removed into ice-cold artificial cerebrospinal 
fluid (aCSF) consisting of (in mM): NaCl 118, KCl 2.5, 
MgSO4 3, NaH2PO4 1.1, NaHCO3 26, CaCl2 1, and glucose 
11 (all reagents from Sigma) bubbled with 95% O2/5% 
CO2. Subsequently, 300-mm-thick coronal slices were cut 
with a vibrotome (MA752, Campden Instruments Ltd., 
UK). The hippocampi were dissected in cold, oxygenated 
Hank’s balanced salt solution (HBSS, Gibco, Invitrogen), 
transferred onto sterile porous membrane confetti 
(Millicell, Millipore, MA, USA), and cultured with their 
standard medium (here referred to as Medium-2) or with 
the MAB-conditioned media (see below). The culture 
medium was changed the day after preparation and then 
every 2 days for the course of the experiment. 
Preparation of the Conditioned Media. The effects 
of the MABs delivering BDNF on cell survival were 
evaluated in several experimental groups cultured with 
a special conditioned media. In the groups “MABs” and 
“MABs-BDNF,” the conditioned media were composed 
by the mixture of equal volumes of fresh MABs grow-
ing medium (Medium-1) and of the 2-day-culture super-
natant from MABs and MABs-BDNF, respectively. The 
group called Medium-1 served as a control, being chal-
lenged with the fresh growing medium. Medium-2 is a 
standard culture medium for OCs from postnatal ani-
mals, consisting of 50% DMEM, 25% horse serum, 18% 
HBSS, 4 mM l-glutamine, 12 mM glucose, 4.5 mM 
NaHCO3, 20 mM sucrose, 100 U/ml penicillin, and 100 
mg/ml streptomycin (Sigma, St. Louis, MO, USA). The 
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other conditioned media were based on the above media 
with different supplementations of reagents, like the recom-
binant human BDNF (0.03–300 ng/ml, Immunological 
Sciences), the BDNF antagonist K252a (50 nM, Sigma), 
or TrkB-IgG (2 μg/ml, R&D Systems, Inc., MN, USA), a 
recombinant tyrosine kinase receptor B (TrkB) engineered 
as an immunoadhesion to sequester BDNF. Sister slices 
were randomly assigned to the different groups.
Viability. The viability of PCs and OCs was assessed 
in two ways. First, the fluorescein diacetate (FDA) hydro-
lysis assay was used to measure enzyme activity in cells. 
Slices have been incubated with 10 mg/ml FDA (Sigma) for 
30 min, then images were captured using an optical micro-
scope (DMRA2, Leica, Germany), and the fluorescence 
intensity was quantified using the software Image-Pro Plus 
6.0 (Media Cybernetics, USA). Second, the lactate dehydro-
genase (LDH) release assay was used to measure cell death. 
The culture medium was all collected, and LDH leakage 
was quantified by using a LDH cytotoxic test kit (Clontech, 
CA, USA) according to the manufacturer’s instructions. 
Immunocytochemistry. Cultured slices were fixed with 
4% PFA in PBS for 1 h at room temperature (RT). After a 
48-h incubation with 30% sucrose at 4°C, slices were sec-
tioned to a thickness of 30 μm in a cryostat (CM1510, Leica, 
Germany). The primary antibody was mouse anti-micro-
tubule-associated protein (MAP2abc; 1:50; Immunological 
Sciences, Italy), and the secondary antibody was Alexa 
Fluor 488 goat anti-mouse IgG (1:100, Invitrogen, CA, 
USA). The slices were mounted onto slides after stain-
ing with 4¢,6-diamidino-2-phenylindole (DAPI, 1:1,000). 
For zif7268, hippocampal neurons were incubated for 
3 h at RT with rabbit anti-zif antibody (Egr-1; Santa Cruz 
Biotechnology, Santa Cruz, CA) diluted 1:1,000 in 10% 
fetal calf serum (FCS) in PBS, followed by fluorescein 
anti-rabbit IgG antibody (Invitrogen, CA, USA).
Western Blot. To estimate the density of the surviv-
ing neurons within a slice, we performed immunoblot 
analysis of the neuron-specific marker neurofilament 
68. After 14 days in culture, slices were rinsed with ice-
cold PBS and then lysed in sample buffer (ECL Western 
blotting kit, GE Healthcare, USA). Aliquots from each 
sample (15 mg protein/lane) were subjected to 10% SDS-
polyacrylamide gel electrophoresis and transferred onto 
polyvinylidine fluoride membranes (Millipore). The 
blots were blocked in blocking buffer (20 mM Tris–HCl, 
137 mM NaCl, and 5% skim milk) for 1 h at room tem-
perature and then treated with anti-neurofilament 68 anti-
body (diluted 1:500; Sigma) overnight at 4°C. Membranes 
were washed repeatedly in Tris-buffered saline containing 
0.05% Tween 20, and then the horse radish peroxidase-
conjugated secondary antibody (diluted 1:20,000) was 
added for 1 h. Immunoreactive bands were detected using 
enhanced luminol-based chemiluminescence (ECL). The 
membranes were stripped, and then immunoblotting for 
b-actin (1:1,000, Sigma, St. Louis, MO, USA) was per-
formed, as a loading control. Bands were scanned into 
digital images and analyzed with the software of Image-
Pro Plus (Media Cybernetics, USA).
Field Potential Recording. After 7 days in culture, 
slices were transferred to a holding chamber for 1 h at 
room temperature in aCSF, while continuously aerated 
with 95% O2 and 5% CO2. Slices were then placed in 
a submerged in vitro recording chamber and perfused 
with oxygenated aCSF. The temperature in the recording 
chamber was kept at 36 ± 1°C. Bipolar wire electrodes 
(tungsten with a tip diameter of 90 mm; WPI, Inc., FL, 
USA) were used for stimulation of the Schaffer collat-
eral pathway in the CA3 region. Glass microelectrodes 
filled with 0.9% NaCl were placed on the CA1 stratum 
radiatum to record field excitatory postsynaptic potential 
(fEPSP). A conventional electrophysiological technique 
for extracellular recordings was employed to identify the 
maximal response and to adjust the stimulus strength. 
The stimulus intensity (70-μs duration rectangular pulses 
at 40 V) that repeatedly evoked the maximal synaptically 
evoked response/excitatory postsynaptic potential was 
used in each slice. Signals were acquired under constant 
conditions and off-line processed using the Patchmaster 
software (HEKA Instruments, Inc., Germany). 
Statistical Analysis of Data
One-way analyses of variance (ANOVA) followed by 
the Newman–Keuls test were used to evaluate the results. 
Effects were considered to be statistically significant at 
the 0.05 probability level.
RESULTS
Selection and Characterization of Mesoangioblast Cells 
Expressing NGF and BDNF
Two DNA constructs were generated, driving the 
expression of murine preproNGF and rat preproBDNF. 
The preproNGF construct contains the cDNA encoding the 
short form (27 kDa) of the NGF precursor (isolated from 
the mouse submaxillary gland), whereas the preproBDNF 
construct contains the cDNA coding for the BDNF precur-
sor (isolated from the rat brain). These constructs are based 
on the scFv-express vector (50), yielding the expression 
vectors ScFv-preproNGF and ScFv-preproBDNF, respec-
tively. In order to evaluate the appropriate expression and 
targeting to secretion of the pro-neurotrophins driven by 
the constructs, COS cells were transiently transfected 
with ScFv-preproNGF or ScFv-preproBDNF. NGF and 
BDNF expression and secretion in the COS medium were 
assessed 72 h after transfection using ELISA. The average 
concentration of NGF was estimated to be approximately 
80 ng/ml and that of BDNF was approximately 190 ng/ml 
(data not shown).
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GFP-expressing MABs (45) were stably transfected 
with either ScFv-preproNGF or ScFv-preproBDNF 
DNA. Clonal selection was performed with G418 and 
limited dilution. Among the different clones analyzed by 
ELISA for neurotrophin production, two were selected: 
clone F10, producing the highest concentration of NGF 
after 4 days in culture, and clone A9, producing the 
highest concentration of BDNF after 15 days in culture. 
These clones were then further characterized for the 
kinetics of NGF and BDNF secretion. For this purpose, 
conditioned medium was collected from F10 cultures 
kept at confluence (3.5 × 104/cm2) 24, 48, 72, and 96 h 
(4 days) in the case of NGF; in the case of BDNF-
expressing MABs (clone A9), mitomycin-treated cells 
were kept for 8, 11, 14, and 15 days. Within these time 
frames, the maximal concentration of NGF was reached 
after 4 days of culture and the one of BDNF after 
15 days. BDNF secretion was very low in the first 
week. The reason(s) for the different kinetics of NGF 
and BDNF secretion are presently under investigation. 
The estimated rate of accumulation was 36 ng/ml/day/ 
106 cells for NGF and 30 ng/ml/day/106 cells for BDNF, 
starting from the 8th day in culture.
To determine if the proneurotrophins were success-
fully processed by intracellular convertases and if the 
secreted forms are indeed mature NGF or BDNF, con-
ditioned media collected from control and transfected 
cells were analyzed. Media from F10 MABs-NGF and 
A9 MABs-BDNF, as well as from control nontransfected 
MABs, were analyzed by Western blot. Only mature 
NGF was detected in the medium of F10 MABs-NGF 
(Fig. 1A). In the medium of A9 MABs-BDNF, proBDNF 
was detectable but in much smaller amounts compared 
with mature BDNF (Fig. 1B). These data indicate that 
MABs-NGF and MABs-BDNF can process the proneuro-
trophins and secrete exclusively or almost exclusively the 
mature form.
Assessment of NGF Biological Activity 
The biological activity of NGF was evaluated using 
the PC12 cell differentiation bioassay (19). Duplicates 
of PC12 cells were challenged with the conditioned 
medium from NGF-producing MABs (clone F10) kept 
in culture for 5 days (containing approximately 80 ng/
ml NGF, based on ELISA), diluted 1:1 with growing 
medium. In alternative, PC12 cells were cocultured with 
F10 cells in a 1:1 ratio. The medium was replaced every 
other day, and PC12 cell differentiation was assessed 
by the presence of neurite elongations and the expres-
sion of the neuronal marker b-tubulin after 7 days. As 
shown in Figure 2, both F10 conditioned medium and 
coculture with F10 cells induced efficient neuronal dif-
ferentiation of PC12 cells similar to that observed upon 
the addition of recombinant NGF (50 ng/ml). Neither 
the conditioned medium from control, untransfected 
MABs, nor coculture with these cells induced PC12 
differentiation.
Assessment of BDNF Biological Activity 
The biological activity of BDNF was evaluated in 
several ways. First (Fig. 3), we measured the nuclear 
accumulation of zif/268 in hippocampal primary cul-
tures (PCs). Zif/268 (Egr1) is a zinc finger protein 
acting as transcription factor, whose nuclear translo-
cation is commonly used to test the biological activity 
of BDNF (51). PCs were challenged for 3 h with the 
conditioned medium from MABs-BDNF (A9 clone), 
collected after 15 days of culture and containing approxi-
mately 87 ng/ml BDNF. Immunofluorescence revealed 
that the nuclear accumulation of zif/268 was increased 
upon addition of A9 conditioned medium (Fig. 3D), 
Figure 1. Production and release of mature neurotrophins by 
mesoangioblasts (MABs). (A) Western blot analysis for nerve 
growth factor (NGF) shows the mature form of the neurotrophin 
(left arrow) in the supernatant of NGF-expressing F10 cells 
(MABs-NGF) but not in normal MABs. The amount of proNGF 
in the medium is negligible. (B) Western blot analysis for brain-
derived neurotrophic factor (BDNF) shows the mature form 
of the neurotrophin (left arrow) in the supernatant of BDNF-
expressing A9 cells (MABs-BDNF) but not in normal MABs. 
proBDNF is detectable in the medium, but in much smaller 
amounts compared with BDNF, indicating a nearly complete 
processing. Multiple bands can be observed for BDNF, likely 
corresponding to posttranslational processing products.
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indistinguishable from what was observed upon addi-
tion of 50 ng/ml recombinant BDNF (rBDNF) (Fig. 3B), 
as compared with untreated neurons (Fig. 3A) and neu-
rons treated with medium conditioned from control 
MABs (Fig. 3C). 
Second, we tested if continuous application of rBDNF 
in the medium exerted trophic effects on cell survival 
in low-density PCs and in organotypic cultures of adult 
hippocampus slices (OCs). Thus, culture media were 
supplemented with increasing concentrations of rBDNF, 
Figure 2. Effects of NGF produced by MABs on PC12 differentiation. PC12 differentiation in the presence of recombinant NGF 
(B, E, H, K), in the presence of conditioned medium from MABs-NGF (C, I), or when cocultured with MABs-NGF (F, L) is visualized 
by the presence of neurites (B–C, E–F) and confirmed by immunofluorescence for the expression of b III-tubulin (Tuj1, red immuno-
staining in H–I, K–L). As negative control, PC12 cells have been cultivated in growing medium without NGF (A, G) or cocultured 
with control MABs (D, J). Scale bars: 25 mm.
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ranging from 0.03 to 300 ng/ml. In PCs, neurons seeded 
at low density can hardly survive without the support 
of rBDNF. Quantification of survival, based on cell 
counting and on LDH release, showed that BDNF pro-
duces a significant beneficial effect in a concentration-
dependent manner (Fig. 4A, B). The maximal effect was 
estimated to be reached at a concentration of approxi-
mately 10−8 M (corresponding to 270 ng/ml) and the 
EC50 was approximately 3 × 10−11 M (slightly less than 
1 ng/ml). These data are in keeping with previous find-
ings (6,37).
We then examined the neurotrophic activities of 
rBDNF in OCs. OCs provide an ideal in vitro model sys-
tem to assess toxic or trophic effects since they preserve 
the morphological and physiological features of the hip-
pocampal neuronal network and allow easy access and 
precise control of extracellular environment for a long 
period (28,57). In general, OCs are prepared from early 
postnatal animals (14) because, when prepared from 
adult hippocampal slices, they rapidly undergo neuronal 
degeneration (64). We elected to employ hippocampal 
cultures prepared from adult animals (66) exactly for 
this reason: they do not survive well in standard cul-
ture media and, thus, may provide a very convincing 
evidence for the favorable effects of the supplementa-
tion of NTFs if they survive when cultured in the MAB 
medium (in this sense, OCs represent an in vitro model 
of neurodegeneration). 
In the absence of rBDNF, OCs displayed degeneration 
aspects (like white spotted cell debris and uneven sur-
face) after 6–8 days in vitro (DIV), which were clearly 
visible under phase contrast microscopy. Similar to PCs, 
rBDNF concentration-dependently reduced these signs 
of degeneration. Viability was quantified using FDA 
fluorescence to identify viable cells and LDH release to 
estimate the degree of cell death. As shown in Figure 4C 
and D, BDNF concentration-dependently increased FDA 
fluorescence and reduced LDH release, in line with 
previous observations reporting that BDNF enhances 
the cell tolerance to serum deprivation of organotypic 
cultures from postnatal slices (48). These effects were 
obtained in the same range of concentrations that proved 
effective for PCs.
As stated above, the amount of BDNF secreted into the 
medium (Medium-1) from MABs-BDNF after 2 days in 
culture was very low: approximately 2 ng/ml, as measured 
using ELISA (Fig. 5). If MABs-BDNF were cultured with 
the medium usually employed to culture OCs (Medium-2), 
the amount of secreted BDNF was approximately halved 
(Fig. 5C). Therefore, although controls were also per-
formed using Medium-2, the conditioned media that we 
used in all experiments was based on Medium-1: 50% 
Figure 3. Effects of BDNF on zif/268 nuclear accumulation in primary rat hippocampal neurons. 
High levels of zif/268 immunostaining are concentrated in the nuclei of cells incubated with recom-
binant BDNF (arrows in B) or conditioned medium from A9 BDNF-producing MABs (arrows in D), 
whereas low level of zif/268 immunostaining is present in the nuclei of hippocampal neurons treated 
with growing medium (A) or medium conditioned from control, D16 MABs (C). Scale bars: 25 mm.
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culture supernatant from 2-day-cultured MABs-BDNF and 
50% fresh Medium-1. This conditioned medium con-
tained approximately 1 ng/ml BDNF, whereas no detect-
able of BDNF was present in the medium conditioned with 
control MABs (Fig. 5C).
We first screened the trophic effects of the MABs-
BDNF-conditioned medium in the PC system. The 
medium conditioned in control MABs increased the num-
ber of surviving neurons by about 80%, similar to the 
effect of 300 ng/ml rBDNF (a maximally effective con-
centration). The effect of the MABs-BDNF-conditioned 
medium was much greater (it enhanced neuronal survival 
by approximately 170%). We used the LDH assay to mea-
sure these effects: as shown in Figure 5D, both 300 ng/ml 
rBDNF and the MABs medium significantly (and to a 
similar extent) reduced cell death, but the MABs-BDNF 
medium had a significantly greater effect. Interestingly, 
1 ng/ml rBDNF (i.e., the concentration of BDNF present 
in the MABs-BDNF medium) alone did not produce any 
significant effect on neuronal survival. Together with the 
observation of a significant effect of the MABs medium, 
this indicates that other trophic factors are secreted 
by MABs that can synergize with BDNF to produce 
neuroprotection. 
We then extended and deepened this analysis in OCs. 
Adult OCs were cultured with the different media, and after 
14 DIV, cell death was measured using the LDH release 
assay. As shown in Figure 5E, cell death was remarkable 
in control media (Medium-1 and Medium-2). As with PCs, 
the MABs-conditioned medium significantly decreased 
cell death to nearly the level of rBDNF 300 ng/ml, and the 
MABs-BDNF-conditioned medium produced a significantly 
Figure 4. Recombinant BDNF enhances cell survival in primary hippocampal neuronal cultures (PCs, 
A and B) and in organotypic adult hippocampus slice cultures (OCs, C and D) in a concentration-
dependant manner. Neurons were cultured with the indicated concentration of BDNF for 7 days, slices 
for 14 days. A and C indicate viable cells, as quantified using cell counting for PCs and fluorescence 
intensity of the marker fluorescein diacetate (FDA) for OCs. B and D represent cell death, as estimated 
measuring the levels of released lactate dehydrogenase (LDH). Data are expressed as the means ± SE 
(n = 6). *p < 0.05, **p < 0.01 versus control (0 ng/ml); ANOVA and post hoc Newman–Keuls test.
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more pronounced effect. This extra effect is mediated by the 
low concentrations (1 ng/ml) of mature BDNF produced 
by the MABs-BDNF, because (i) adding 1 ng/ml rBDNF 
to the MABs medium produced an effect similar to the one 
produced by the MABs-BDNF medium; (ii) adding the 
TrkB inhibitor K252a and the BDNF scavenger TrkB-IgG 
to the medium conditioned by MABs-BDNF abolished the 
extra effect observed in the MABs-BDNF group, while 
these two BDNF blockers had no significant influence on 
the medium conditioned by MABs (Fig. 5E). These data 
support the notion that the prosurvival effect of the MABs-
BDNF medium is mediated by a synergy between BDNF 
and other, yet unidentified, soluble substances constitutively 
produced by MABs. Accordingly, 1 ng/ml rBDNF alone 
did not reduce cell death at all, and much higher concentra-
tions (300 ng/ml) were needed to approach the effect of the 
MABs-BDNF-conditioned medium. 
These findings have been confirmed using light micros-
copy and FDA fluorescence, an indicator of viable cells 
(Fig. 6). At the bright field observation, as compared with 
slices cultured in the control medium (these slices, as 
described, display obvious signs of degeneration) ( Fig. 6A), 
the slices cultured in the medium conditioned on MABs-
BDNF remained thicker and preserved their structural 
organization for a long period, up to 25 days (Fig. 6C). 
Slices cultured in the MABs medium appeared healthier 
Figure 5. MABs-BDNF deliver BDNF and enhance cell survival in primary hippocampal neuronal cultures (PC) and in organotypic 
adult hippocampus slice cultures (OC). (A and B) Genetically modified MABs-BDNF proliferate and express green fluorescent protein 
(GFP). (C) MABs-BDNF secrete BDNF. Concentration of BDNF in the medium of MABs and MABs-BDNF at various days in vitro 
(DIV), as measured using ELISA. MABs-BDNF were cultured in two different types of medium (Medium-1 and Medium-2, see text 
for details) as indicated. (D) Effect of different treatment procedures on the viability of hippocampal PCs, as estimated using the LDH 
release assay. Data are the means ± SE of six separate experiments. **p < 0.01 versus Control-1; ●p < 0.05 versus MABs; ANOVA and 
post hoc Newman–Keuls test. (E) Effect of different treatment procedures on the viability of adult hippocampus OCs, as estimated using 
the LDH release assay. Data are the means ± SE of six separate experiments. *p < 0.05 and **p < 0.01 versus Control-1; ●p < 0.05 versus 
MABs; ▲p < 0.05 versus MABs-BDNF; ANOVA and post hoc Newman–Keuls test. Control-1 are slices treated with the typical medium 
for MABs culture (Medium-1). Control-2 are slices treated with the typical medium for postnatal slice culture (Medium-2). Scale bars: 
25 mm (A and B).
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than those cultured in control medium but less healthy than 
those cultured in the MABs-BDNF medium (Fig. 6B). In 
line with these findings and paralleling the high levels of 
LDH release described above, FDA fluorescence was weak 
and uneven in OCs cultured with control medium (Fig. 6D), 
indicating that most of the cells are indeed degenerating. 
OCs cultured with the MABs medium displayed a better 
labeling quality (Fig. 6E), which was further improved in 
OCs cultured with the MABs-BDNF medium (Fig. 6F).
Cell counting, performed by using the DAPI nuclear 
staining, confirmed that, even if some cell loss was pres-
ent in slices cultured with MABs-BDNF-conditioned 
medium (Fig. 6I), the number of surviving cells was much 
higher than in the control group (Fig. 6G). Slices treated 
with the medium conditioned in MABs performed a little 
better than controls, but much worse than those treated 
with the medium conditioned in MABs-BDNF (Fig. 6H).
Other morphological examinations and electrophysi-
ological recordings were performed. For morphologi-
cal analysis, slices were fixed and immunostained with 
MAP2, a cytoskeletal protein primarily found in neuronal 
dendrites. As shown in Figure 6J, adult slices cultured in 
the control media for 14 days exhibit not only extensive 
cell loss, but also a grossly altered structure, with many 
lacunae in the pyramidal cell layer and just a few remain-
ing, exclusively pyknotic neurons. MAP2 staining was 
essentially absent in control slices. While the MABs 
medium only slightly improved this situation (Fig. 6K), 
the MABs-BDNF-conditioned one clearly attenuated neu-
ronal loss (Fig. 6L). Furthermore, the dendritic network 
and the cytoarchitectonic characteristics were essentially 
maintained in adult OCs treated with the MABs-BDNF-
conditioned medium, even if some signs of neuronal 
degeneration could be detected (loss of neurons, decreased 
dendrites, condensed or swelling pyramidal cells). These 
signs of degeneration progressively increased in time. This 
morphological analysis further confirms that the medium 
conditioned in MABs-BDNF enhances neuronal survival 
and delays the alterations in structural organization. 
The density of neurons in OCs was also assessed using 
Western blot analysis for the neuron-specific marker 
neurofilament 68 (NF68). We found that OCs cultured 
on MABs-BDNF-conditioned medium contained more 
NF68, thus more neurons, as compared with slices cul-
tured in the control medium or in medium from conven-
tional MABs (Fig. 7). A statistically significant difference 
Figure 6. Morphological evidence of the beneficial effects of the medium conditioned in MABs-BDNF on adult organotypic cultures. 
Adult slices were cultured for 14 days with the control Medium-1, with medium conditioned in MABs, or with medium conditioned 
in MABs-BDNF. Note that slices cultured in the MABs-BDNF-conditioned medium, compared with the other two groups, better 
maintain their integrity based on bright field observation (A–C) and remain more viable based on FDA (D–E), DAPI staining (G–I), 
and microtubule-associated protein 2 (MAP2) immunohistochemistry (J–L). Nuclei in blue in G–I; neurons in green in J–L. Scale bar: 
1 mm (scale bar in C also refers to A and B; scale bar in F also refers to D and E; scale bar in I also refers to G and H; scale bar in L 
also refers to J and K).
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was also found between MABs and control group, indi-
cating that supplementation of the soluble substances 
produced by MABs can slightly attenuate neuronal loss.
Finally, we performed electrophysiological recordings 
to demonstrate the viability of the surviving neurons and 
the persistence of synaptic connections at a functional 
level. Thus, fEPSPs in CA1 pyramidal neurons have been 
measured after stimulation of the Schaffer collaterals. We 
chose 7 DIV as a check time point, because adult slices 
in culture, even those cultured with the MABs-BDNF-
conditioned medium, display a progressive decrease 
in the amplitude and stability of the extracellular field 
potentials in time (data not shown). Such currents could 
not be reliably measured at 14 DIV, when neurons are 
still visible using immunofluorescence: as expected, the 
functional damage precedes the morphological one. As 
shown in Figure 8A, adult slices cultured with the typical 
medium exhibited very small (if any) synaptic response at 
7 DIV, while relatively stable fEPSPs could be recorded 
in those cultured with the medium conditioned in MABs 
or MABs-BDNF. However, the mean amplitude of the 
evoked fEPSPs in the MABs-BDNF group was much 
Figure 7. Density of neurons surviving in adult slices after 14 
days in vitro under the different experimental conditions. Neuronal 
density was quantified performing Western blot analysis for a 
neuron-specific marker, neurofilament 68. (A) Representative blot. 
(B) Data quantification. The data are means ± SE of four separate 
experiments. *p < 0.05 and **p < 0.01 versus Control-1; ●●p < 0.01 
versus MABs; ANOVA and post hoc Newman–Keuls test.
 
Figure 8. Maintenance of synaptic connections in adult slices 
after 7 days in culture with the MABs-BDNF-conditioned medium. 
Syn aptic connections were identified by recording evoked field 
excitatory postsynaptic potential (fEPSP) in CA1 after stimula-
tion of the Schaffer collaterals. (A) Representative recordings of 
the evoked fEPSP in the different groups. (B) Peak amplitude of 
the fEPSPs, measured and statistically analyzed as described in 
Materials and Methods. The data are the means ± SE of five sepa-
rate experiments. **p < 0.01 versus Control-1; ●●p < 0.01 versus 
MABs; ANOVA and post hoc Newman–Keuls test.
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higher than in the MABs group (Fig. 8B). The presence 
of evoked synaptic responses, albeit lower and less stable 
than in acute slices or in cultured postnatal slices, demon-
strates that the neuronal activity and the hippocampal cir-
cuitry remain functional by virtue of the beneficial effects 
of the mediators secreted by MABs-BDNF.
DISCUSSION
Main Findings 
In this study, we generated MABs that can stably 
secrete the neurotrophins NGF or BDNF in their mature 
form and found that media conditioned from the culture 
supernatant of these cells exert trophic effects in vitro: 
PC12 cells are induced to differentiation by a MABs-
NGF-conditioned medium, while viability and function 
of cultured neurons and brain slices are increased by a 
MABs-BDNF-conditioned medium. MABs-BDNF effects 
are TrkB receptor-dependent, being abolished by the recep-
tor blocker K252a or by the BDNF scavenger TrkB-IgG. 
Thus, MABs produce robust bystander effects on the ner-
vous tissue that we characterized using endpoints (neuronal 
differentiation, neuroprotection, function) that are relevant 
for neurodegenerative diseases (or, more in general, neuro-
logical diseases associated with damage). 
Therapeutic Efficacy of NGF and BDNF  
in Neurodegeneration
A large body of evidence shows the essential role played 
by NGFs in the adult CNS. In particular, basal forebrain 
cholinergic neurons (BFCNs) that are selectively vulner-
able and hit in AD (1) depend on NGF for their function 
and maintenance of cholinergic phenotype (17,55). BFCNs 
express NGF receptors (21,22), retrogradely transport NGF 
from their cortical projections up to their cell bodies (12), 
and respond to administration of exogenous NGF increas-
ing cholinergic markers (17,46). Moreover, NGF can pre-
vent BFCNs death or atrophy (21,29,63,65).
A pivotal protective role of NGF in neurodegeneration 
has also been shown in AD patients. Clinical trials are cur-
rently underway using intracerebral delivery systems that 
by-pass the BBB. For example, a phase 1 clinical trial used 
stereotaxic intracerebral transplants of autologous fibro-
blasts engineered to produce NGF, achieving a consistent 
reduction in the progression of cognitive decline (62). 
Promising results from another Phase 1 clinical trial, evalu-
ating the safety and efficacy of stereotactic intracerebral 
injections of adeno-associated virus (AAV) harboring the 
NGF gene have recently been reported (41). Unfortunately, 
an invasive surgical step is required for these approaches. 
One alternative may be the delivery of NGF through the 
olfactory route, a less invasive approach that proved capable 
to achieve pharmacologically relevant NGF concentrations 
in the brain of animals (3,9,10). In one study (10), nasal 
NGF delivery reverted the neurodegenerative phenotype 
in an Alzheimer’s disease (AD) model, in the absence of 
appreciable side effects. The drawback of this approach is 
that it requires repeated injections for a prolonged period. 
BDNF is also known to exert neuroprotective effects. For 
example, exogenous BDNF has been reported to increase 
survival of neurons in cultures, while reduced survival was 
found after addition of anti-BDNF antibodies and in BDNF 
knockout mice (38,43). BDNF appears to be an essential 
constituent of the microenvironment for neuronal survival in 
the adult hippocampus. It potentiates presynaptic release and 
excitatory transmission (24,25,35) and promotes dendritic 
and axonal growth (30). Moreover, several investigations 
indicate a pivotal role of BDNF in neuroprotection in dif-
ferent in vivo models of disease, including ischemia (27,32) 
and seizures (18,31). The signaling mechanisms underlying 
the prosurvival effects of BDNF appear to involve TrkB 
activation. TrkB receptors have long been known to medi-
ate trophic support of adult neurons (13), and a number of 
studies show that decreased expression of the receptor is 
associated with cell loss (44). Coherently with these data, 
we demonstrated here the beneficial effects of rBDNF or 
MABs-delivered BDNF on cell survival in primary neu-
ronal and in adult slice cultures, effects that were TrkB 
receptor-dependent. We also observed that MABs-delivered 
BDNF facilitates synaptic responses, an effect that may be 
ascribed to a better preservation of synaptic connection or to 
a potentiation of synaptic transmission. It has been reported 
that BDNF modulates the strength of existing synaptic con-
nections (24,25) and favors the formation of new synaptic 
contacts within the hippocampal circuits (33). 
Similar to NGF, clinical trials have been also under-
taken with BDNF (both peripherally administered and 
delivered directly in the CNS) for the treatment of neu-
rological diseases (56,60). Unfortunately, data have been 
negative thus far.
Synergy Between MAB-Produced Trophic Factors 
We found that the amount of BDNF released by MABs-
BDNF produced greater effects than the identical amount 
of rBDNF, suggesting either that the specific activity of 
MAB-released BDNF is higher than that of rBDNF (pos-
sibly due to a better folding of BDNF released by MABs) 
or that other neurotrophic factors produced by MABs 
synergize with BDNF. A microarray analysis of gene 
expression in MABs revealed that several growth factors 
are expressed at high level in these cells, including VEGF 
B, FGF-2, FGF-7, PDGF AA, and others (15). Although 
it remains unknown which of these NTFs may exert neu-
roprotective effects, it seems very likely that they will 
interact and possibly synergize with BDNF. 
Regardless of the underlying mechanisms, the markedly 
beneficial effects of MABs-delivered NTFs on neurons 
and brain tissue suggest that exogenous, MAB-mediated, 
administration of BDNF or NGF (maybe synergizing with 
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other MAB-produced NTFs) might be developed into a 
strategy for functional preservation and restoration in neu-
rological diseases associated with brain damage. In this 
prospect, a very attractive property of MABs is their poten-
tial to reach the lesioned tissue when peripherally admin-
istered, because this would represent a net advantage over 
other currently tested delivery strategies. MABs have been 
reported to home in damage areas like skeletal muscle (53) 
and myocardial tissue (15) after systemic infusion. 
Conclusions: Potential Advantages of MABs as a 
Delivery Strategy 
The supplementation of NTFs can sustain the survival 
and functional recovery of neurons by modulating the 
postinjury microenvironment. However, NTF delivery to 
the nervous system should be target-specific and region-
ally restricted, prolonged (although not necessarily last-
ing for life), safe, well tolerated, and sufficiently robust 
to elicit responses from target neurons. MAB-based NTF 
delivery may be optimal to meet these criteria. MABs 
possess the advantages of all cell-based therapies: they 
can be expanded to virtually unlimited numbers in vitro; 
they are amenable to genetic modification; they have self-
renewal and multipotent capacities. Moreover, (1) they 
may be used for autologous transplants (can be prepared 
from biopsies from the patient himself); (2) they may be 
peripherally administered (no need for surgery); (3) they 
may selectively home in the lesioned area (recruitment at 
the neuroinflammated site), with no undesired accumula-
tion of NTF in areas that do not need them (reduced side 
effects); (4) at the site of accumulation, they may act as 
efficient bioreactors producing robust bystander effects. 
Further studies will be required to verify the selec-
tive homing of MABs in lesioned areas after peripheral 
administration. If these new studies will be successful, 
MABs might be developed into a new cell-based strat-
egy for NTF delivery into the CNS, promoting neuronal 
survival and restoring network function in neurological 
diseases associated with brain damage.
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